GlaxoSmithKline PLC Reports Strong 2Q Earnings, Beating Analyst Estimates

• In the second quarter of 2023, GlaxoSmithKline (GSK) reported an adjusted earnings per share (EPS) of 38.8p, beating the consensus estimate of 34.7p.
• Revenue for the quarter was GBP7.18 billion, higher than the estimated GBP6.8 billion.
• Adjusted operating profit was GBP2.17 billion, surpassing the estimate of GBP2.01 billion.
• Analysts have given GSK a rating of 10 buys, 14 holds, and 4 sells.

A look at GlaxoSmithKline PLC Smart Scores

GlaxoSmithKline PLC, a research-based pharmaceutical company, has a long-term outlook that is positive overall. The company has been given a Smartkarma Smart Score of 3 for Dividend, 4 for Growth, and 3 for Momentum. This indicates that the company is likely to continue providing a steady dividend, and is likely to experience strong growth and momentum going forward. The company’s Value and Resilience scores are slightly lower at 2, but this is still a positive sign for the company’s future outlook.

GlaxoSmithKline PLC is a leader in the pharmaceutical industry, developing, manufacturing, and marketing vaccines, prescription and over-the-counter medicines, and health-related consumer products. The company offers products for infections, depression, skin conditions, asthma, heart and circulatory disease, and cancer, and is well-positioned for long-term success. With its strong scores in Dividend, Growth, and Momentum, GlaxoSmithKline PLC is likely to remain a leader in the industry for years to come.

Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.

💡 Before it’s here, it’s on Smartkarma